You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
高豐(02863.HK)擬向日企購癌症藥品之目標權利 總代價3,807萬元
阿思達克 10-21 08:44
高豐集團控股(02863.HK)公布,與日企EPS益新株式會社訂立收購協議,向EPS收購目標權利及國家藥品監督管理局之技術服務支持,收購代價分別為987萬元及2,820萬元,收購代價總額為3,807萬元。收購代價將通過按每股代價股份0.47元之發行價,發行8,100萬股代價股份之方式結付,佔擴大後股本10.99%,而發行價較其昨日收市價折讓約14.5%。

該目標權利是藥品於大中華地區之67%之開發、生產及分銷權利,而藥品是通過採用於2000年在日本發現之永生化細胞表達減弱基因之基因治療針對癌症治療法開發出的產品,於今年在美國進入臨床II期試驗。

此外,公司計劃向商人王元元配售1,260萬股股份,佔擴大後股本1.71%,每配售價同為0.47元,集資590萬元,將用於收購事項完成後六個月內在中國設立新的營業點,及進一步研發向國家藥品監督管理局登記的藥品。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account